WO2006088129A1 - プロリン誘導体の塩、またはその溶媒和物、及びその製造方法 - Google Patents
プロリン誘導体の塩、またはその溶媒和物、及びその製造方法 Download PDFInfo
- Publication number
- WO2006088129A1 WO2006088129A1 PCT/JP2006/302827 JP2006302827W WO2006088129A1 WO 2006088129 A1 WO2006088129 A1 WO 2006088129A1 JP 2006302827 W JP2006302827 W JP 2006302827W WO 2006088129 A1 WO2006088129 A1 WO 2006088129A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- salt
- solvate
- hydrate
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to 3- ⁇ (2S, 4S) -4- [4- (3-methyl-1-phenol) useful as a dipeptidyl peptidase IV (hereinafter referred to as DPP-IV) inhibitor.
- DPP-IV dipeptidyl peptidase IV
- DPP-IV inhibitors inhibit the inactivity of glucagon-like peptide-1 (hereinafter referred to as GLP-1) in plasma and enhance its incretin action. It is in the research and development stage as a drug that is useful as a drug that can be effective in the treatment of diabetes, particularly type 2 diabetes (see Patent Documents 1 to 6 and Non-Patent Document 1).
- Compound I 3- ⁇ (2 S, 4S) -4- [4- (3-methyl-1-phenol-1H-pyrazole-5- ) Piperazine-1-yl] pyrrolidin-2-ylcarbonyl ⁇ thiazolidine (hereinafter referred to as Compound I).
- Compound I is described in the form of the trihydrochloride salt, but this salt has pharmaceutically undesirable properties in terms of stability and hygroscopicity and is difficult to manufacture in the same form with reproducibility. It was recognized that In order to meet the regulatory requirements in drug development, in particular, certain quality compounds must be produced reproducibly, so these properties found in the trihydrochloride of Compound I are important for drug development. It is considered disadvantageous.
- Patent Document 7 “I Compound I” and other salts of other thiazolidine derivatives are disclosed as example compounds. There has been a discussion about polymorphism.
- crystal polymorphism The ability of a substance to crystallize into two or more crystal structures is known as polymorphism, and individual crystal forms are called crystal polymorphs. Different crystal polymorphs of the same compound may have completely different physical properties such as storage stability and solubility. these Differences in physical properties may lead to differences in action effects. Because of these differences, the study of individual crystal polymorphs and mixtures of crystal polymorphs is particularly useful in drug development.
- Patent Document 1 International Publication No. 97/040832 Pamphlet
- Patent Document 2 Pamphlet of International Publication No. 98/019998
- Patent Document 3 US Pat. No. 5,939,560
- Patent Document 4 International Publication No. 01/055105 Pamphlet
- Patent Document 5 International Publication No. 02/002560 Pamphlet
- Patent Document 6 International Publication No. 02/062764 Pamphlet
- Patent Document 7 International Publication No. 02/014271 Pamphlet
- Non-Patent Document 1 J. Med. Chem., 47 (17), 4135-4141 (2004)
- An object of the present invention is to provide a compound I having excellent characteristics in terms of stability, solubility, hygroscopicity, bioavailability, and the like, and a reproducible crystal structure, which are desired for a pharmaceutical product. And to provide a method for producing them.
- the present inventors prepared one or more tribasic acid salts of Compound I, characterized the crystals of the respective salts or their solvates, and preferred in terms of stability and hygroscopicity. Has ⁇ characteristics A new salt of Compound I was found. As a result of further intensive studies, the inventors have found a stable industrial preparation method for the novel salt of the present invention and have completed the present invention.
- the gist of the present invention resides in the following salts (1) to (33) or a solvate thereof, and a production method thereof.
- Organic or inorganic monobasic acids are hydrochloric acid, hydrobromic acid, nitric acid, mesylic acid, tosylic acid, besylic acid, hydrochloric acid, naphthalene-1-sulfonic acid, naphthalene-2-sulfonic acid, gallic acid, Is camphorsulfonic acid, the salt according to the above (1), or a solvate thereof (however, when the monobasic acid is hydrochloric acid, the salt is 2 or 2.5 hydrochloride),
- Solubility in water at ambient temperature is 7 mg / mL! And 2 g / mL monobasic acid and 3- ⁇ (2S, 4S) -4- [4- (3-methyl-1-phenol -L-1H-pyrazole-5-yl) piperazine-1-yl] pyrrolidine-2-ylcarbol ⁇ thiazolidine salt, or a solvate thereof,
- the diffraction angle represented by 20 has peaks at 5.4 °, 13.4 °, 14.4 °, 22.6 ° and 26.5 ° (each ⁇ 0.2 °). (14) or a hydrate thereof,
- the acceptable solvent is water and / or the solvent selected in the “residual solvent Q3C ICH guidelines” with a daily intake allowance (“PDE”) exceeding 10 mg / day.
- PDE daily intake allowance
- Each of the novel crystalline polymorphs of a salt of Compound I or a solvate thereof has improved stability, improved hygroscopicity (deliquescent), rapid isolation from the solvent, and formulation Has one or more properties selected from the ease of preparation and facilitates the development of Compound I as a pharmaceutical.
- FIG. 1 is a measurement result of powder X-ray diffraction of the title compound of Example 4.
- the Y axis is the diffraction intensity, and the horizontal axis is the diffraction angle (2 ⁇ ).
- FIG. 2 is a measurement result of powder X-ray diffraction of the compound of Example 5 (1).
- the Y axis is the diffraction intensity, and the horizontal axis is the diffraction angle (2 ⁇ ).
- FIG. 3 is a measurement result of powder X-ray diffraction of the compound of Example 5 (2).
- the Y axis is the diffraction intensity, and the horizontal axis is the diffraction angle (2 ⁇ ).
- FIG. 4 is a result of measuring powder X-ray diffraction of the compound of Example 5 (3).
- the Y axis is the diffraction intensity, and the horizontal axis is the diffraction angle (2 ⁇ ).
- FIG. 5 is a measurement result of hygroscopicity of the title compound of Example 3.
- 101 is the adsorption of water to the compound at the horizontal axis humidity
- ⁇ ichi is the water desorption from the compound at the horizontal axis humidity.
- the trihydrochloride of compound I can be produced according to the synthesis method described as Example 222 of WO 02/14271.
- This base uses an appropriate base such as an alkali metal or alkaline earth metal carbonate (sodium bicarbonate, sodium carbonate, or potassium carbonate) or an alkali metal or alkaline earth metal hydroxide. (Such as sodium hydroxide or potassium hydroxide).
- a hydrocarbon solvent such as benzene or toluene
- a halogenated hydrocarbon solvent dimethoxycarbon solvent
- dichloromethane, dichloroethane, chloroform, or Compound I can be obtained by extraction with tetrasalt, carbon, etc.
- ethyl acetate ethyl acetate
- the 2.5 hydrobromide salt of Compound I can also be produced by the following scheme.
- This reductive amination reaction is carried out with respect to 1 mol of the compound represented by the formula (II) or a salt thereof.
- the compound represented by the formula (III) is used in an amount of about 0.5 to 10 mol, preferably about 1 to 2 mol, and a metal hydride complex (sodium borohydride, sodium cyanoborohydride, triacetoxy borohydride).
- a complex hydrogen compound such as sodium or diborane is used in an amount of about 0.5 to 10 moles, preferably about 1 to 2 moles, and an acidic catalyst (acetic acid, P-toluenesulfonic acid, or In an inert solvent in the presence of boron fluoride 'jetyl ether complex, etc.).
- inert solvents examples include alcohols (methanol, ethanol, 1-propanol, 2-propanol (hereinafter referred to as IPA), butanol, etc.), nitriles (acetonitrile, propio-tolyl, etc.), Amides (formamide, ⁇ , ⁇ -dimethylformamide, ⁇ , ⁇ -dimethylacetamide, or 1,3-dimethyl-2-imidazolidinone), ethers (jetyl ether, diisopropyl ether, t- Butyl methyl ether, 1,4-dioxane, or tetrahydrofuran (hereinafter referred to as THF)), halogenated hydrocarbons (such as dichloromethane, chloroform, or 1,2-dichloroethane), hydrocarbons ( n-hexane, cyclohexane, benzene, toluene, etc.), or any mixed solvent thereof.
- alcohols m
- the reaction temperature is -20 to 200 ° C, preferably 0 to 80 ° C, and the reaction time is about 0.5 to 96 hours, preferably 0.5 to 24 hours.
- the reaction temperature is ⁇ 20 to 200 ° C., preferably 0 to 100 ° C., and the reaction time is about 0.5 to 48 hours, preferably 0.5 to 24 hours.
- the salt represented by the formula (IV) can be obtained by filtering the precipitate.
- the form of the salt of the present invention is not particularly limited, and may be an oily substance, amorphous (amorphous), or crystalline.
- a preferred salt form is a crystal.
- Examples of the salt in the form of crystals include 2.0 hydrochloride, 2.5 hydrochloride, dihydrobromide, 2.5 odorous hydrochloride, 2 mesylate, 3 mesylate, 2 tosylate, 2-besylate, 2-naphthalene-1-sulfonate, 2-naphthalene-2-sulfonate, 2 (+)-camphorsulfonate, 2 maleate, 2 fumarate, or 2L-tartrate, etc. Can be illustrated. These salts can also be characterized by diffraction peaks in the powder X-ray diffraction pattern.
- the crystal polymorphs of 2.0 hydrobromide are referred to as Form A, Form B and Form C.
- the salt in the crystalline form is also referred to herein as 2.0 hydrobromide, where appropriate.
- the crystal polymorphs of 2-tosylate are A, B and C
- the crystals of 2-tosylate are A, B and C
- the crystals of 2-besylate are A.
- Forms B and B, 2 maleate crystal polymorphs are referred to as A and B forms
- 2 fumarate crystal polymorphs are referred to as A and B forms, respectively.
- the solvate of the salt of the present invention may exist as a solvate such as hemi, mono-, di-, tri-, tetra-, penta, hexa and the like.
- Solvents used for crystallization (alcohols (such as methanol, ethanol, or IPA), aldehydes, ketones (such as acetone), or esters (such as ethyl acetate)) and water contained in these solvents are contained in the crystal lattice. Can be incorporated. In general, it is impossible to predict the force at which a solvent will become a solvate or a non-solvate during crystallization and subsequent manufacturing steps. They depend on the compound, the production conditions and the combination of various interactions between the chosen solvent, especially water.
- the salt of the present invention may be a solvate of a solvent (such as water or an organic solvent) or a non-solvate. That is, the salt of the present invention may be a hydrate or a non-hydrate. May be. In the case of a hydrate, the amount of water to be hydrated may vary depending on various conditions, but is preferably a hydrate of 2.0 or less, more preferably 1.0 to 2.0 hydrate.
- the salt of the present invention may contain a solvent that is safe for mammals (such as those that are pharmaceutically, pharmacologically, or physiologically acceptable), or may be solvated with the solvent. May be.
- solvents are those whose daily intake allowance (“PDE”) exceeds 10 mg / day in the “ICH Guidelines for Residual Solvent Q3C” and / or classes in the “ICH Guidelines for Residual Solvent Q3C” The power of 3 is also chosen.
- ethanol 1-propanol, IPA, 1-butanol, 2-butanol, 1-pentanol, acetic acid, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate
- examples include formic acid, ethyl formate, acetone, methyl ethyl ketone, methyl isobutyl ketone, heptane, pentane, jetyl ether, t-butyl methyl ether, THF, anisole, tamen, and dimethyl sulfoxide.
- solvents ethanol is preferred.
- the content of “solvent” is 50000 ppm or less, preferably 5000 ppm or less.
- the salt of the present invention can be produced by a method known per se, for example, Compound I, hydrochloric acid, hydrobromic acid, nitric acid, mesylic acid, maleic acid, tosylic acid, besylic acid, naphthalene-1 -Sulfonic acid, naphthalene-2-sulphonic acid, gallic acid, (+) _ camphorsulphonic acid, (-)-camphorsulfonic acid, fumaric acid, sulfuric acid, succinic acid, L-tartaric acid, ethanedisulfonic acid, Chenic acid or phosphoric acid power
- the salt of the present invention can be obtained by reacting with a selected organic acid or inorganic acid.
- This reaction is generally performed in the absence of a solvent or in an inert solvent.
- inert solvents include water, alcohols (such as methanol, ethanol, 1-propanol, IPA, or butanol), ketones (such as acetone or methyl ethyl ketone), and nitriles (acetonitrile).
- amides (formamide, ⁇ , ⁇ -dimethylformamide, ⁇ , ⁇ -dimethylacetamide, or 1,3-dimethyl-2-imidazolidinone), ethers (jet ether, Diisopropyl ether, t-butyl methyl ether, 1,4-dioxane, or THF), esters (such as ethyl formate, ethyl acetate, or propyl acetate), halogenated hydrocarbons (dichloromethane, chloroform, Or 1,2-dichloroethane, etc.), carbonization Examples include hydrogens (such as n- hexane, cyclohexane, benzene, or toluene), sulfoxides (such as dimethyl sulfoxide), polar solvents (such as sulfolane or hexamethylphosphorylamide), or any mixed solvent thereof. It is done. Among these solvents,
- the "inert solvent” is generally used in an amount of 1 to 100 w / v%, preferably 2 to 50 w / v%, relative to Compound I.
- the reaction temperature is usually ⁇ 20 ° C. and the reflux temperature of the solvent, preferably 0 ° C. and the reflux temperature of the solvent.
- the reaction time is usually about 1 minute to 24 hours, preferably about 10 minutes to 6 hours, more preferably about 30 minutes to 3 hours.
- the salt thus obtained is isolated from the reaction mixture by a separation means known per se (concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography, etc.) It can be purified.
- the salt of Compound I can be obtained in the crystalline state.
- crystallization method include those known per se, such as crystallization from solution, crystallization from steam, and crystallization of melt strength (AS Myerson Ed., Handbook of Industrial, rystallization second Edition, Butterworth— Heinemann 200 2).
- Examples of the method for "crystallization of solution force" include a concentration method, a slow cooling method, a reaction method (diffusion method or electrolysis method), a hydrothermal growth method, a flux method, and the like.
- Examples of the solvent to be used include the same solvents as the “inert solvent”.
- Examples of the method of "vapor-powered crystal” include a vaporization method (a sealed tube method or a gas flow method), a gas phase reaction method, a chemical transport method, and the like.
- crystallization of the salt of Compound I crystallization by cooling of a solution in which the salt of Compound I is dissolved by heating to 40 ° C to the reflux temperature of the solvent used, or the salt of Compound I is used. Crystallization or the like by adding a poor solvent to a solution (particularly concentrated solution) in which is dissolved.
- an X-ray analysis method is generally used as a method for analyzing the obtained crystal. The measurement results of X-ray analysis show that the force 2 ⁇ value expressed as the diffraction intensity on the Y axis and the diffraction angle (2 ⁇ ) on the horizontal axis varies within a certain range even when the same crystal form is measured. Is observed.
- ⁇ 0.2 ° is a general variation, but a larger error may occur depending on the measurement conditions.
- those skilled in the art will compare crystal forms in consideration of these variations.
- the salt of the present invention or a solvate thereof may cause a slight shift in diffraction angle depending on the water content, and these are also included in the scope of the present invention.
- the salt of the present invention or a solvate thereof (hereinafter simply referred to as the salt of the present invention) has excellent stability, it can be stored at room temperature over a long period of time, and it is a complicated operation in the production process and storage. It is useful as a drug substance for pharmaceuticals because it is not necessary and it is easy to formulate. Furthermore, since the salt of the present invention has high solubility in water, a dosage form with a higher degree of freedom can be developed as an injectable preparation.
- the carrier of the present invention is pharmaceutically acceptable (excipient, binder, disintegrant, flavoring agent, flavoring agent, emulsifier, diluent, or solubilizer) and the like.
- Pharmaceutical compositions or formulations obtained by mixing (tablets, pills, capsules, granules, powders, syrups, emulsions, elixirs, suspensions, solutions, injections, drops, or sittings) In the form of an agent etc.) orally or parenterally.
- the pharmaceutical composition can be formulated according to a usual method.
- parenteral includes subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, infusion method, and the like.
- injectable preparations can be prepared by methods known in the art.
- Suppositories for rectal administration can be prepared by mixing the drug with an appropriate excipient.
- solid dosage forms for oral administration include those mentioned above such as powders, granules, tablets, pills, capsules and the like.
- liquid preparations for oral administration include pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, and solutions.
- the dosage of the salt of the present invention is the age, body weight, general health condition, sex, meal, administration time, dosage. It will be determined by considering these and other factors depending on the method of administration, the rate of excretion, the combination of drugs, or the condition of the patient being treated at the time.
- the salt of the present invention can be used safely with low toxicity, and its daily dose varies depending on the patient's condition, body weight, type of salt, route of administration, etc.
- 0.05 to 50 mg / kg body weight / day is administered in one to several times a day.
- thermal analysis shows the temperature at the intersection (onset value) on the extension of the straight line part before melting and the straight line part during melting in the heat curve (onset value) and the temperature at the inflection point near the melting point ( peak top value).
- the powder X-ray diffraction pattern showed a characteristic peak at an angle of 2 ⁇ ( ⁇ 0.2 °) o-NMR was measured with a 300 MHz nuclear magnetic resonance spectrometer.
- the chemical shift of ' ⁇ - ⁇ MR was expressed in parts per million (ppm) using tetramethylsilane (TMS) as an internal standard and relative delta ( ⁇ ) values.
- Coupling constants indicate trivial multiplicity in hertz (Hz), expressed as s (singlet), d (doublet), t (triplet), m (multiplet), etc.
- Infrared spectroscopic (IR) absorbance intensities were expressed as st (strong), m (medium), and w (weak).
- Example 1 60 mg of the title compound of Example 1 was suspended in 3.0 mU of ethyl acetate and heated to reflux for 13 hours. After cooling at room temperature, the precipitate was collected by filtration and dried under hot air at 40 ° C. to give the title compound as crystals (50 mg yield 85%).
- This toluene layer was washed with 90 L of 5% aqueous sodium hydrogen carbonate solution and 90 L of water in this order, and concentrated to dryness under reduced pressure.
- 224 L of IPA was added, and 25.08 kg of 48% hydrobromic acid was added dropwise at about 80 ° C., followed by refluxing for 2.5 hours.
- the reaction was cooled and stirred at about 60 ° C for 1.5 hours, then at about 40 ° C for 2 hours, and further at room temperature for 2 hours.
- the precipitate was collected by filtration, washed with IPA 30 L, and dried under warm air to give the title compound solid (29.76 kg, yield 91%).
- Test example 1 [0065] Measurement of powder X-ray diffraction
- FIG. 2 shows the result of the powder X-ray diffraction measurement of the A-form crystal of the title compound of Example 5.
- FIG. 3 shows the result of the powder X-ray diffraction measurement of the B-form crystal of the title compound of Example 5.
- FIG. 4 shows the results of powder X-ray diffraction measurement of the C-form crystal of the title compound of Example 5.
- Test example 2 shows the results of the powder X-ray diffraction measurement of the A-form crystal of the title compound of Example 5.
- FIG. 3 shows the result of the powder X-ray diffraction measurement of the B-form crystal of the title compound of Example 5.
- FIG. 4 shows the results of powder X-ray diffraction measurement of the C-form crystal of the title compound of Example 5.
- the moisture absorption property of the title compound of Example 3 was measured using a moisture adsorption measuring device under the following measurement conditions.
- a visual method was used which can easily grasp the maximum solubility with a small amount of sample.
- the temperature was measured at 37 ° C.
- About 3 mg of the title compound of Example 3 was placed in a sample bottle with a screw cap, and 0.15 mL of the test solution was collected and sealed. After the sample was dispersed by applying ultrasonic waves for 1 minute, this was added together and placed in a constant-temperature shaking water bath stabilized at 37 ° C. After shaking for 1 hour, dissolution was confirmed by visual observation.
- the solubility of the title compound of Example 3 in water was 20 mg / mL or more at 37 ° C.
- the salt of Compound I or its solvate, or each new crystalline polymorph has improved stability, improved hygroscopicity (deliquescent), rapid isolation from solvents, and ease of formulation. Promote the development of Compound I as a pharmaceutical product with one or more selected properties [0070] This application was filed with priority from Japanese Patent Application No. 2005-04-1851.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES06713968.3T ES2588164T3 (es) | 2005-02-18 | 2006-02-17 | Sal de un derivado de prolina, solvato del mismo, y método de producción de los mismos |
JP2007503744A JP4208938B2 (ja) | 2005-02-18 | 2006-02-17 | プロリン誘導体の塩、またはその溶媒和物、及びその製造方法 |
NZ561489A NZ561489A (en) | 2005-02-18 | 2006-02-17 | Salt of proline derivative, solvate thereof, and production method thereof |
EA200701756A EA013119B1 (ru) | 2005-02-18 | 2006-02-17 | Соль производного пролина, ее сольват и способ ее получения |
KR1020137016412A KR20130076903A (ko) | 2005-02-18 | 2006-02-17 | 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법 |
CA2598301A CA2598301C (en) | 2005-02-18 | 2006-02-17 | Salt of proline derivative, solvate thereof, and production method thereof |
EP06713968.3A EP1854795B1 (en) | 2005-02-18 | 2006-02-17 | Salt of a proline derivative, solvate thereof, and production method thereof |
US11/816,493 US8003790B2 (en) | 2005-02-18 | 2006-02-17 | Salt of proline derivative, solvate thereof, and production method thereof |
KR1020077021144A KR101352650B1 (ko) | 2005-02-18 | 2006-02-17 | 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법 |
CN2006800048659A CN101119991B (zh) | 2005-02-18 | 2006-02-17 | 脯氨酸衍生物的盐,其溶剂合物,及其生产方法 |
AU2006215041A AU2006215041B2 (en) | 2005-02-18 | 2006-02-17 | Salt of proline derivative, solvate thereof, and production method thereof |
BRPI0607863A BRPI0607863B8 (pt) | 2005-02-18 | 2006-02-17 | sal cristalino 2,5-bromidrato de 3-{(2s,4s)-4-[4-(3-metil-1-fenil-1h-pirazol-5-il)piperazin-1-il]pirrolidin-2-ilcarbonil}tiazolidina e seu processo de preparo |
US13/194,501 US8604198B2 (en) | 2005-02-18 | 2011-07-29 | Salt of proline derivative, solvate thereof, and production method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005041851 | 2005-02-18 | ||
JP2005-041851 | 2005-02-18 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/816,493 A-371-Of-International US8003790B2 (en) | 2005-02-18 | 2006-02-17 | Salt of proline derivative, solvate thereof, and production method thereof |
US13/194,501 Continuation US8604198B2 (en) | 2005-02-18 | 2011-07-29 | Salt of proline derivative, solvate thereof, and production method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006088129A1 true WO2006088129A1 (ja) | 2006-08-24 |
Family
ID=36916526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/302827 WO2006088129A1 (ja) | 2005-02-18 | 2006-02-17 | プロリン誘導体の塩、またはその溶媒和物、及びその製造方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US8003790B2 (ja) |
EP (2) | EP2602259A3 (ja) |
JP (3) | JP4208938B2 (ja) |
KR (2) | KR20130076903A (ja) |
CN (3) | CN102372704B (ja) |
AU (1) | AU2006215041B2 (ja) |
BR (1) | BRPI0607863B8 (ja) |
CA (1) | CA2598301C (ja) |
EA (1) | EA013119B1 (ja) |
ES (1) | ES2588164T3 (ja) |
MX (1) | MX2007010054A (ja) |
NZ (1) | NZ561489A (ja) |
TW (1) | TWI403511B (ja) |
WO (1) | WO2006088129A1 (ja) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008120813A1 (ja) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | ジペプチジルペプチダーゼ4阻害化合物と甘味料との併用 |
WO2010079197A1 (en) | 2009-01-07 | 2010-07-15 | Boehringer Ingelheim International Gmbh | Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor |
WO2010086411A1 (en) | 2009-01-29 | 2010-08-05 | Boehringer Ingelheim International Gmbh | Dpp-iv inhibitors for treatment of diabetes in paediatric patients |
WO2010092163A2 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
WO2011064352A1 (en) | 2009-11-27 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
WO2011074660A1 (ja) | 2009-12-18 | 2011-06-23 | 田辺三菱製薬株式会社 | 溶出安定性製剤 |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012165547A1 (ja) * | 2011-06-01 | 2012-12-06 | 田辺三菱製薬株式会社 | ピラゾール誘導体の製造方法 |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US8853385B2 (en) | 2008-01-17 | 2014-10-07 | Mitsubishi Tanabe Pharma Corporation | Combination therapy comprising SGLT inhibitors and DPP4 inhibitors |
EP2990037A1 (en) | 2008-08-06 | 2016-03-02 | Boehringer Ingelheim International GmbH | Treatment for diabetes in patients inappropriate for metformin therapy |
JP2019512460A (ja) * | 2017-02-03 | 2019-05-16 | グレンマーク・ファーマシューティカルズ・リミテッド | テネリグリプチンのシュウ酸塩およびその溶媒和物を含む製剤 |
EP3626238A1 (en) | 2008-08-15 | 2020-03-25 | Boehringer Ingelheim International GmbH | Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients |
JP2021522332A (ja) * | 2018-04-25 | 2021-08-30 | 乳源▲東▼▲陽▼光▲薬▼▲業▼有限公司 | テネリグリプチン臭化水素酸塩アモルファス及びその調製方法 |
JP2022069426A (ja) * | 2020-10-23 | 2022-05-11 | マイラン ラボラトリーズ リミテッド | テネリグリプチン2.5臭化水素酸塩のアモルファスを調製する方法 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006088129A1 (ja) * | 2005-02-18 | 2006-08-24 | Mitsubishi Pharma Corporation | プロリン誘導体の塩、またはその溶媒和物、及びその製造方法 |
US20090088442A1 (en) * | 2005-04-26 | 2009-04-02 | Mitsubishi Tanabe Pharma Corporation | Prophylactic/therapeutic agent for abnormalities of sugar/lipid metabolism |
CA2844388A1 (en) | 2011-08-19 | 2013-02-28 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
MX370649B (es) | 2012-08-31 | 2019-12-19 | Glenmark Pharmaceuticals Ltd | Proceso para la preparacion de teneligliptina. |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
CN104230917B (zh) * | 2013-06-24 | 2017-04-05 | 南京华威医药科技开发有限公司 | 一种脯氨酸衍生物盐的水合物及其生产方法 |
WO2015019239A1 (en) | 2013-08-06 | 2015-02-12 | Ranbaxy Laboratories Limited | Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine |
WO2015019238A1 (en) | 2013-08-06 | 2015-02-12 | Ranbaxy Laboratories Limited | Process for the preparation of n-protected (5s)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one |
WO2015063709A1 (en) | 2013-10-31 | 2015-05-07 | Ranbaxy Laboratories Limited | Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine |
CN104650065A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种替格列汀化合物 |
WO2015173779A1 (en) | 2014-05-16 | 2015-11-19 | Micro Labs Limited | Process for the preparation of teneligliptin and its novel intermediates |
CN105294673B (zh) * | 2014-06-18 | 2018-04-13 | 四川科伦药物研究院有限公司 | 一种氢溴酸替格列汀的合成方法 |
CN108727364A (zh) * | 2017-04-18 | 2018-11-02 | 乳源东阳光药业有限公司 | 一种氢溴酸替格列汀无定型及其制备方法 |
KR102494848B1 (ko) | 2018-10-10 | 2023-02-02 | 주식회사 파마코스텍 | 테네리글립틴 2토실산염 2수화물의 결정형 ⅰ형 및 그 제조방법 |
KR20200127480A (ko) | 2019-05-02 | 2020-11-11 | 연성정밀화학(주) | 테네리글립틴 에디실산염 결정형 및 이의 제조방법 |
KR20210121421A (ko) | 2020-03-30 | 2021-10-08 | 코오롱생명과학 주식회사 | 테네리글리프틴 2.5브롬화수소산염 무정형의 제조방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002014271A1 (fr) | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Dérivés de proline et leur utilisation comme médicaments |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
US4337341A (en) * | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
AU2790895A (en) * | 1994-06-10 | 1996-01-05 | Universitaire Instelling Antwerpen | Purification of serine protease and synthetic inhibitors thereof |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
US20030176357A1 (en) * | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
JP2003520849A (ja) | 2000-01-24 | 2003-07-08 | ノボ ノルディスク アクティーゼルスカブ | 酵素dpp−ivの阻害剤であるn−置換2−シアノピロールおよび−ピロリン |
EP1301187B1 (en) | 2000-07-04 | 2005-07-06 | Novo Nordisk A/S | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
ATE366724T1 (de) | 2001-02-02 | 2007-08-15 | Takeda Pharmaceutical | Kondensierte heterocyclische derivate |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
CN100341862C (zh) * | 2001-09-14 | 2007-10-10 | 三菱制药株式会社 | 噻唑烷衍生物及其医药用途 |
WO2004099134A2 (en) * | 2003-05-05 | 2004-11-18 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
AU2003902946A0 (en) * | 2003-06-12 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
JP4569802B2 (ja) | 2003-07-23 | 2010-10-27 | 眞 八藤 | ビタミンを主材とするイオン化ミネラル結合型サプリメントの製造方法 |
WO2006088129A1 (ja) * | 2005-02-18 | 2006-08-24 | Mitsubishi Pharma Corporation | プロリン誘導体の塩、またはその溶媒和物、及びその製造方法 |
US20090088442A1 (en) | 2005-04-26 | 2009-04-02 | Mitsubishi Tanabe Pharma Corporation | Prophylactic/therapeutic agent for abnormalities of sugar/lipid metabolism |
PL1894567T3 (pl) | 2005-06-03 | 2013-01-31 | Mitsubishi Tanabe Pharma Corp | Środki farmaceutyczne do podawania skojarzonego oraz ich zastosowanie |
-
2006
- 2006-02-17 WO PCT/JP2006/302827 patent/WO2006088129A1/ja active Application Filing
- 2006-02-17 BR BRPI0607863A patent/BRPI0607863B8/pt not_active IP Right Cessation
- 2006-02-17 NZ NZ561489A patent/NZ561489A/en not_active IP Right Cessation
- 2006-02-17 TW TW095105368A patent/TWI403511B/zh not_active IP Right Cessation
- 2006-02-17 AU AU2006215041A patent/AU2006215041B2/en not_active Ceased
- 2006-02-17 KR KR1020137016412A patent/KR20130076903A/ko not_active Application Discontinuation
- 2006-02-17 EP EP13157384.2A patent/EP2602259A3/en not_active Withdrawn
- 2006-02-17 JP JP2007503744A patent/JP4208938B2/ja active Active
- 2006-02-17 US US11/816,493 patent/US8003790B2/en not_active Expired - Fee Related
- 2006-02-17 EA EA200701756A patent/EA013119B1/ru not_active IP Right Cessation
- 2006-02-17 ES ES06713968.3T patent/ES2588164T3/es active Active
- 2006-02-17 CA CA2598301A patent/CA2598301C/en not_active Expired - Fee Related
- 2006-02-17 MX MX2007010054A patent/MX2007010054A/es active IP Right Grant
- 2006-02-17 CN CN201110303552.6A patent/CN102372704B/zh active Active
- 2006-02-17 KR KR1020077021144A patent/KR101352650B1/ko active IP Right Review Request
- 2006-02-17 CN CN2011103035812A patent/CN102372705A/zh active Pending
- 2006-02-17 EP EP06713968.3A patent/EP1854795B1/en not_active Not-in-force
- 2006-02-17 CN CN2006800048659A patent/CN101119991B/zh not_active Ceased
-
2008
- 2008-04-30 JP JP2008119236A patent/JP2008214358A/ja active Pending
-
2011
- 2011-07-29 US US13/194,501 patent/US8604198B2/en not_active Expired - Fee Related
-
2012
- 2012-10-10 JP JP2012224923A patent/JP2013032376A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002014271A1 (fr) | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Dérivés de proline et leur utilisation comme médicaments |
Non-Patent Citations (1)
Title |
---|
See also references of EP1854795A4 |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008120813A1 (ja) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | ジペプチジルペプチダーゼ4阻害化合物と甘味料との併用 |
US8853385B2 (en) | 2008-01-17 | 2014-10-07 | Mitsubishi Tanabe Pharma Corporation | Combination therapy comprising SGLT inhibitors and DPP4 inhibitors |
EP2990037A1 (en) | 2008-08-06 | 2016-03-02 | Boehringer Ingelheim International GmbH | Treatment for diabetes in patients inappropriate for metformin therapy |
EP3598974A1 (en) | 2008-08-06 | 2020-01-29 | Boehringer Ingelheim International GmbH | Treatment for diabetes in patients inappropriate for metformin therapy |
EP3626238A1 (en) | 2008-08-15 | 2020-03-25 | Boehringer Ingelheim International GmbH | Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients |
WO2010079197A1 (en) | 2009-01-07 | 2010-07-15 | Boehringer Ingelheim International Gmbh | Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor |
WO2010086411A1 (en) | 2009-01-29 | 2010-08-05 | Boehringer Ingelheim International Gmbh | Dpp-iv inhibitors for treatment of diabetes in paediatric patients |
WO2010092163A2 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
WO2011064352A1 (en) | 2009-11-27 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
TWI418370B (zh) * | 2009-12-18 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 溶出安定性製劑 |
US9572806B2 (en) | 2009-12-18 | 2017-02-21 | Mitsubishi Tanabe Pharma Corporation | Elution-stabilized preparation |
WO2011074660A1 (ja) | 2009-12-18 | 2011-06-23 | 田辺三菱製薬株式会社 | 溶出安定性製剤 |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
JPWO2012165547A1 (ja) * | 2011-06-01 | 2015-02-23 | 田辺三菱製薬株式会社 | ピラゾール誘導体の製造方法 |
WO2012165547A1 (ja) * | 2011-06-01 | 2012-12-06 | 田辺三菱製薬株式会社 | ピラゾール誘導体の製造方法 |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
JP2019512460A (ja) * | 2017-02-03 | 2019-05-16 | グレンマーク・ファーマシューティカルズ・リミテッド | テネリグリプチンのシュウ酸塩およびその溶媒和物を含む製剤 |
JP2021522332A (ja) * | 2018-04-25 | 2021-08-30 | 乳源▲東▼▲陽▼光▲薬▼▲業▼有限公司 | テネリグリプチン臭化水素酸塩アモルファス及びその調製方法 |
JP2022069426A (ja) * | 2020-10-23 | 2022-05-11 | マイラン ラボラトリーズ リミテッド | テネリグリプチン2.5臭化水素酸塩のアモルファスを調製する方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4208938B2 (ja) | プロリン誘導体の塩、またはその溶媒和物、及びその製造方法 | |
US9452169B2 (en) | Substituted diketopiperazines and their use as oxytocin antagonists | |
CA3218212A1 (en) | Substituted triazine compound | |
TW202112768A (zh) | 二取代吡唑化合物 | |
TW201920196A (zh) | 作為vanin抑制劑之雜芳族化合物 | |
CN107922385A (zh) | Cgrp受体拮抗剂 | |
JP2024001040A (ja) | 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態 | |
JP7424639B2 (ja) | 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態 | |
US20130060030A1 (en) | Process for the preparation of highly pure crystalline imatinib base | |
JP6087035B1 (ja) | 新規3−アザビシクロ[3.1.0]ヘキサン誘導体の塩の結晶及びその医薬用途 | |
KR101865868B1 (ko) | 1-이소프로필-3-[5-[1-(3-메톡시프로필) 피페리딘-4-일]-[1,3,4]옥사디아졸-2-일]-1h-인다졸 옥살레이트의 대규모 제조공정 | |
KR20110023887A (ko) | CBı-길항 활성을 갖는 플루오로-치환된 3,4-디아릴-4,5-디하이드로-1H-피라졸-1-카복스아미딘 유도체 | |
US20090233967A1 (en) | Crystalline forms of mc4r agonist and process for synthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007503744 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680004865.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2598301 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/010054 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3176/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006215041 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 561489 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077021144 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006713968 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200701756 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2006215041 Country of ref document: AU Date of ref document: 20060217 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006215041 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11816493 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2006713968 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0607863 Country of ref document: BR Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020137016412 Country of ref document: KR |